| scholarly article | Q13442814 |
| P50 | author | Bernard Moss | Q822617 |
| P2093 | author name string | Peterson J | |
| Broder CC | |||
| Earl PL | |||
| Chakrabarti S | |||
| Long D | |||
| Doms RW | |||
| Lee SA | |||
| P2860 | cites work | Multimeric CD4 binding exhibited by human and simian immunodeficiency virus envelope protein dimers | Q24630280 |
| Site-directed mutagenesis by overlap extension using the polymerase chain reaction | Q27860503 | ||
| Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase | Q27860943 | ||
| Folding and assembly of viral membrane proteins | Q27865318 | ||
| Complete nucleotide sequence of the AIDS virus, HTLV-III | Q28259080 | ||
| The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus | Q28259668 | ||
| Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein | Q28646759 | ||
| Identification of the fusion peptide of primate immunodeficiency viruses | Q28646799 | ||
| Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1 | Q28646812 | ||
| T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV | Q28646817 | ||
| The structure and function of the hemagglutinin membrane glycoprotein of influenza virus | Q29618354 | ||
| A general model for the transmembrane proteins of HIV and other retroviruses | Q30395640 | ||
| Monoclonal Antibodies to the Extracellular Domain of HIV-1IIIB gp160 that Neutralize Infectivity, Block Binding to CD4, and React with Diverse Isolates | Q30778843 | ||
| Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees | Q33582665 | ||
| Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. | Q33685950 | ||
| Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein | Q34097650 | ||
| A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells | Q42802044 | ||
| Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in Vitro | Q43917849 | ||
| B Cell Epitope Mapping of Human Immunodeficiency Virus Envelope Glycoproteins with Long (19- to 36-residue) Synthetic Peptides | Q43950591 | ||
| Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV. | Q44021595 | ||
| A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity | Q44119196 | ||
| HIV requires multiple gp120 molecules for CD4-mediated infection | Q44171806 | ||
| Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein | Q44509170 | ||
| Immunogenicity and Epitope Mapping of a Recombinant Soluble gp160 of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein | Q44830160 | ||
| Antibody Epitopes Sensitive to the State of Human Immunodeficiency Virus Type 1 gp41 Oligomerization Map to a Putative α-Helical Region | Q45237075 | ||
| Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing | Q45252128 | ||
| Epitopes of human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins recognized by antibodies in the sera of HIV-1-infected individuals | Q45859839 | ||
| Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) | Q45860192 | ||
| A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum | Q46622394 | ||
| Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. | Q48378749 | ||
| Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. | Q55241600 | ||
| Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. | Q55244821 | ||
| Discontinuous epitopes on gp120 important in HIV-1 neutralization | Q67465908 | ||
| Comparative immunogenicity of gp120-derived proteins and their induction of anti-V3 loop region antibodies | Q67802612 | ||
| Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site | Q67897903 | ||
| Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS | Q68181056 | ||
| Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120 | Q72067428 | ||
| Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein | Q34301897 | ||
| A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope | Q34614992 | ||
| Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins | Q35076867 | ||
| Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans | Q36641374 | ||
| CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion. | Q36641527 | ||
| Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals | Q36641676 | ||
| Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons | Q36655953 | ||
| Neutralization of HIV‐1: a paradox of humoral proportions | Q36661766 | ||
| Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein | Q36684443 | ||
| Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody | Q36687562 | ||
| Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses | Q36687749 | ||
| Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. | Q36694332 | ||
| gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains | Q36701542 | ||
| Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles | Q36793670 | ||
| Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding | Q36795606 | ||
| Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. | Q36806386 | ||
| Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages | Q36820658 | ||
| A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120. | Q36821056 | ||
| Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody | Q36821885 | ||
| Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1 | Q36828367 | ||
| Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope | Q36869394 | ||
| Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in continuous cell lines | Q36872227 | ||
| Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity | Q36873079 | ||
| Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. | Q36881981 | ||
| Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody | Q37399845 | ||
| Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody | Q37603996 | ||
| A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. | Q37634237 | ||
| Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein | Q37675018 | ||
| Protein oligomerization in the endoplasmic reticulum | Q38737584 | ||
| Regulation of protein export from the endoplasmic reticulum | Q39544463 | ||
| Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. | Q40059306 | ||
| Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody | Q40062738 | ||
| Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein | Q41544160 | ||
| Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes | Q41562736 | ||
| Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein | Q41570066 | ||
| Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. | Q41588189 | ||
| Generation and characterization of a human monoclonal antibody that neutralizes diverse HIV-1 isolates in vitro | Q41643892 | ||
| An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection | Q41679452 | ||
| The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing | Q41712188 | ||
| Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120 | Q42129803 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 3015-3026 | |
| P577 | publication date | 1994-05-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities | |
| P478 | volume | 68 |
| Q36637598 | A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus |
| Q28299280 | A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies |
| Q36363866 | A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays |
| Q39588870 | A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure |
| Q33826951 | Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity |
| Q39577162 | Antibody-Dependent Cellular Cytotoxicity Directed against Cells Expressing Human Immunodeficiency Virus Type 1 Envelope of Primary or Laboratory-Adapted Strains by Human and Chimpanzee Monoclonal Antibodies of Different Epitope Specificities |
| Q36267348 | Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs |
| Q35930918 | Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies |
| Q36178167 | Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. |
| Q64973575 | B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques. |
| Q36954635 | Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. |
| Q33930424 | Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus |
| Q35774051 | Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site |
| Q31016954 | Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. |
| Q34030981 | Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules. |
| Q34471760 | Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region |
| Q39592994 | Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein |
| Q35651494 | Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop |
| Q34302085 | Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants |
| Q33806056 | Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins |
| Q37596552 | Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 |
| Q37318042 | Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation |
| Q52721542 | Comparison of Uncleaved and Mature Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimers. |
| Q24561905 | Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies |
| Q37834097 | Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies |
| Q34465510 | Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles |
| Q35825546 | Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. |
| Q36488676 | Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines |
| Q37059997 | Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes |
| Q33274285 | Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies |
| Q33788810 | Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains |
| Q37346420 | Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines |
| Q35832875 | Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. |
| Q36625449 | Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 |
| Q38989507 | Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits |
| Q34999946 | Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates. |
| Q33571825 | Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein |
| Q35596474 | Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer |
| Q40346734 | Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120. |
| Q37422543 | Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. |
| Q37248017 | Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection |
| Q40839976 | Emerging studies of human HIV-specific antibody repertoires |
| Q35666057 | Engineering, Expression, Purification, and Characterization of Stable Clade A/B Recombinant Soluble Heterotrimeric gp140 Proteins |
| Q36532471 | Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. |
| Q36549107 | Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope |
| Q35880289 | Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein |
| Q27469367 | Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. |
| Q37099872 | Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion |
| Q35860996 | Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. |
| Q24675302 | Functional and structural interactions between measles virus hemagglutinin and CD46 |
| Q35168642 | Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. |
| Q30857503 | Generation of recombinant vaccinia viruses via green fluorescent protein selection |
| Q33826382 | Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1 |
| Q40961265 | HIV preventive vaccines. Progress to date |
| Q92495399 | HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions |
| Q34999293 | Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin |
| Q35869312 | Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein |
| Q36365085 | Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer |
| Q35854300 | Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. |
| Q33643223 | Identification of CXCR4 domains that support coreceptor and chemokine receptor functions |
| Q33835295 | Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. |
| Q33836042 | Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers |
| Q35874414 | In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope |
| Q33784777 | Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins |
| Q34754733 | Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system |
| Q37123584 | Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein |
| Q36380741 | Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization |
| Q34976881 | Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. |
| Q35647772 | Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer |
| Q37245921 | Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes |
| Q35192782 | Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 |
| Q33804811 | Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution |
| Q92883468 | Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity |
| Q36808080 | Multivariate analysis of human immunodeficiency virus type 1 neutralization data |
| Q36565090 | N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus |
| Q37633417 | Native-like Env trimers as a platform for HIV-1 vaccine design |
| Q40295939 | Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives |
| Q33870236 | Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. |
| Q33783516 | Neutralizing Antibodies in Sera from Macaques Infected with Chimeric Simian-Human Immunodeficiency Virus Containing the Envelope Glycoproteins of either a Laboratory-Adapted Variant or a Primary Isolate of Human Immunodeficiency Virus Type 1 |
| Q34637968 | Neutralizing Antibody Responses in Macaques Induced by Human Immunodeficiency Virus Type 1 Monovalent or Trivalent Envelope Glycoproteins |
| Q30431941 | Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 |
| Q39880496 | Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46 |
| Q39684388 | Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein |
| Q34343380 | Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface |
| Q43124783 | Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution |
| Q33413784 | Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery |
| Q39868309 | Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. |
| Q64080897 | Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus |
| Q36954218 | Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras |
| Q33737723 | Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells |
| Q42166543 | Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. |
| Q34332284 | Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus |
| Q39484956 | Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate |
| Q35853761 | Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i |
| Q33996980 | Recombinant vaccinia viruses. Design, generation, and isolation |
| Q35833044 | Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus |
| Q33794954 | Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. |
| Q35887822 | Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. |
| Q34055984 | Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange |
| Q34361680 | Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. |
| Q40301176 | Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity |
| Q39602726 | Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers |
| Q33785383 | Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting |
| Q35879339 | Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant |
| Q35881351 | The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions |
| Q28646857 | The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide |
| Q34610233 | The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes |
| Q35741691 | The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages |
| Q35784690 | Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein |
| Q34391256 | Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. |
| Q38976471 | Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events |
| Q39585034 | Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits |
Search more.